entimICER DARE dramatically improves how pharmaceutical companies can manage, analyze, and report on clinical data.
Paris – 06/03/2006 – entimo AG, a leading company providing manufacturers of the pharmaceutical and crop science industries with high quality e-business Research & Development (eR&D) products and solutions, as well as custom IT solutions for the regulatory authorities, today announced the general availability of its flagship product entimICE DARE to all customers worldwide.
entimICE DARE is a comprehensive and flexible product that ensures seamless operation across different stages of clinical development by enabling the user to view, manage, analyze and report data across clinical applications, and across projects or trials, within the same environment, and in a regulatory compliant manner. entimICE DARE is designed to meet the needs of clinical research and development personnel - such as clinical monitors, clinical research associates, biostatisticians, programmers, etc. - involved in the integration, management, analysis and reporting of clinical trial data. Now pharmaceutical companies can have a customizable repository based data analysis and reporting environment that is cost effective, easy to implement, and tailored to their business - all without having to write a single line of code.
"entimICE DARE is filling the gap of traceability between CDMS and submission in a customizable manner" said Juergen Spieler, chief executive officer of entimo AG. "With this release, entimo AG raises the bar for clinical data repository based solutions for managing, analyzing and reporting of clinical data, delivering pharmaceutical companies unprecedented value. The enhanced functionality that our entimICE DARE solution provides enables pharmaceutical companies of all sizes to meet the increasing demands of regulatory compliance, such as GxP and CFR Part 11, head-on, while providing them the flexibility to customize their solution based on their unique business requirements."
entimICE DARE provides:
General features
Regulatory compliance
Secure access
Structure definition
Traceability
Workflow
Data management
Statistical analysis and program management and execution
For more information, please visit the company's website at www.entimo.com.
Final ENLIVEN Trial Results Confirm Long-Term Benefit of Turalio in Tenosynovial Giant Cell Tumor
July 9th 2025In final data from the Phase III ENLIVEN study, Turalio (pexidartinib) demonstrated durable tumor responses and a consistent safety profile in patients with symptomatic TGCT not amenable to surgery.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
Effect of AI/ML, Real World Evidence and Master Protocols on Trial Success
July 7th 2025How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical oversight and increased collaboration, are contributing to better healthcare delivery and strengthening the role of clinical research in driving global health progress.